Exhibits
10-K
from 10-K
155 pages
10-K
03/28/24
EX-4.1
from 10-K
5 pages
Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
03/28/24
EX-10.13
from 10-K
15 pages
Amended and Restated Executive Employment Agreement
03/28/24
EX-10.15
from 10-K
4 pages
Second Amendment to Oncosignature Companion Diagnostic Agreement
03/28/24
EX-10.16
from 10-K
5 pages
Certain Confidential Information, Marked by [***], Has Been Excluded From This Exhibit Because It (I) Is Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Third Amendment to Oncosignature Companion Diagnostic Agreement This Third Amendment to Oncosignature Companion Diagnostic Agreement (The “Third Amendment”) Is Made and Entered Into as of December 4, 2023 (The “Third Amendment Effective Date”) by and Between: Acrivon Therapeutics, Inc., a Delaware Corporation With Its Principal Place of Business at 480 Arsenal Way, Suite 100, Watertown, Ma 02472 (“Acrivon”), and Akoya Biosciences, Inc., a Delaware Corporation With Its Principal Place of Business at 100 Campus Drive, 6th Floor, Marlborough, Ma 01752 (“Akoya”). Acrivon and Akoya Are Each Referred to Individually as a “Party” and Together as the “Parties.”
03/28/24
EX-21.1
from 10-K
2 pages
Subsidiaries of the registrant
03/28/24
EX-23.1
from 10-K
2 pages
Consent of expert or counsel
03/28/24
EX-31.1
from 10-K
2 pages
Management certification of annual or quarterly disclosure
03/28/24
EX-31.2
from 10-K
2 pages
Management certification of annual or quarterly disclosure
03/28/24
EX-32.1
from 10-K
2 pages
Management certification of financial report
03/28/24
EX-32.2
from 10-K
2 pages
Management certification of financial report
03/28/24
EX-97.1
from 10-K
6 pages
03/28/24
Graphics & Data Files
GRAPHIC
from 10-K
img242192837_0.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_1.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_2.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_3.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_4.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_5.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_6.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_7.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_8.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_9.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_10.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_11.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_12.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_13.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_14.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_15.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_16.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_17.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_18.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_19.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_20.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_21.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_22.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_23.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_24.jpg
03/28/24
GRAPHIC
from 10-K
img242192837_25.jpg
03/28/24
